CIPLA
|
|
BOM : 500087     NSE : CIPLA     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Average [Stock is fairly valued] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Upward Pledged Shares : None or < 25% |
Mar 18,2024 |
Price(EOD): ₹ 1,487.35
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 120,088.64 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
CIPLA | 1.5% | 3.3% | 70.6% |
SUN PHARMACEUTICAL INDUSTRIES | -0.8% | 4% | 61.6% |
DIVIS LABORATORIES | -2.1% | -6% | 26.4% |
DR REDDYS LABORATORIES | 0.7% | 0.4% | 44.6% |
TORRENT PHARMACEUTICALS | -4% | -2.8% | 70.3% |
ABBOTT INDIA | 6% | -3% | 39.7% |
ZYDUS LIFESCIENCES | 0.3% | 11.1% | 109.1% |
ALKEM LABORATORIES | -1.5% | -8.6% | 63.1% |
LUPIN | -2% | -0.5% | 149.9% |
FUNDAMENTAL ANALYSIS OF CIPLA
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF CIPLA
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
32.07
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 3,744.03 Cr
[Latest Qtr - Dec2023 - Consolidated Results ] 5.14
P/B Calculated based on Book Value of Rs 23,346.00 Cr
[Latest Year - Mar2023 - Consolidated Results ] 4.74
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 25,350.20 Cr
[Latest Qtr - Dec2023 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
11% 5% 10% |
SHARE PRICE MOMENTUM OF CIPLA
CIPLA vs SENSEX
DEBT OF CIPLA
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2023 2022 2021 Avg_3yrs |
0 0 0 - |
0.02 0.04 0.1 0.05 |
[Last Annual Data : Mar2023]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF CIPLA
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF CIPLA
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-1.11% 0.79% -7.55% -7.55% |
13.66% 24.15% 21% 32.23% |
QtrlyTrend |
2 | |
Latest Qtr: Dec2023 | ||
Quarterly Result Analysis → |
CIPLA related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE SENSEX50 | -1.3% | 0.6% | 28.2% |
S&P BSE 100 ESG INDEX | -1.4% | 0% | 25.6% |
S&P BSE LARGECAP | -1.5% | 0.6% | 31.1% |
S&P BSE CARBONEX | -1.5% | 0.3% | 31.2% |
S&P BSE 100 LARGECAP TMC | -1.6% | 0.5% | 32.4% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY GROWTH SECTOR 15 | 1.2% | 11.6% | 9.1% |
NIFTY QUALITY LOW-VOLATILTY 30 | -0.8% | 0.6% | 34.7% |
NIFTY 50 | -1.2% | 0.7% | 28.6% |
NIFTY100 LOW VOLATILITY 30 | -1.5% | 0.3% | 39.6% |
NIFTY 100 | -1.6% | 0.6% | 32.6% |
You may also like the below Video Courses
FAQ about CIPLA
Is CIPLA good for long term investment?
As on Mar 18,2024, the Fundamentals of CIPLA look Strong and hence it may be good for long term investment! See Financial Performance of CIPLA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is CIPLA UnderValued or OverValued?
As on Mar 18,2024, CIPLA is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of CIPLA ?
As on Mar 18,2024, the Intrinsic Value of CIPLA is Rs. 1,348.02 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 1,344.98
Fair Value [Median EV / Sales Model] : Rs. 1,416.13
Fair Value [Median Price / Sales Model] : Rs. 1,348.02
Estimated Median Fair Value of CIPLA : Rs. 1,348.02
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.